Original-Research: HBM Healthcare Investments AG (von Edison Investment Resea...

Original-Research: HBM Healthcare Investments AG - von Edison Investment Research Limited

Einstufung von Edison Investment Research Limited zu HBM Healthcare Investments AG

Unternehmen: HBM Healthcare Investments AG

ISIN: CH0012627250

Anlass der Studie:

Letzte Ratingänderung:

Analyst: Sarah Godfrey

London, UK, 2 March 2016

Edison initiates coverage on HBM Healthcare Investments

Edison Investment Research, a leading international investment research

firm, announces the initiation of full coverage of HBM Healthcare

Investments

Highlights of the analysis on HBM Healthcare Investments by Edison's

investment trust analysts Sarah Godfrey and Andrew Mitchell are as follows:

HBM Healthcare Investments (HBMN) is a Swiss investment company that

invests in healthcare companies globally. Its portfolio is spread across

private companies, private equity funds and public holdings, many of which

began in the private portfolio. After a buoyant IPO cycle it currently has

a relatively low proportion invested in private companies (14% at 31

December versus an average since inception in 2001 of 35.6%), but this is

set to rise, with $17.5m already committed to two new private investments

so far in 2016. HBMN invests broadly across healthcare (diversified by

sector, geography and company size) rather than concentrating on the

recently more volatile area of biotechnology. It has outperformed the MSCI

World Health Care Index over one and three years. Each year 5-8% of NAV is

expected to be returned to shareholders through a combination of share

buybacks and capital distributions (current yield of 5.6%).

HBM Healthcare Investments (previously HBM BioVentures, renamed in 2012)

aims to generate long-term gains through investment in private and public

companies in the human medicine, biotech, medtech and diagnostics sectors,

and related areas. It invests worldwide, predominantly in private

companies, either directly or through funds, and many of its publicly

listed holdings began as private equity investments.

Click here to view the full report

All reports published by Edison are available to download free of charge

from its website:

www.edisoninvestmentresearch.com

About Edison: We are an international equity advisory firm. We enable our

client companies to achieve their capital market objectives. The team is

made up of more than 80 analysts and investment professionals with many

decades of experience. Our extensive company knowledge and industry

expertise spans 10 business sectors and more than 700 listed companies

globally. We give our corporate clients and investors privileged insight

into global investment trends. Our distribution capability is key to

ensuring that a global investor audience can access our investment

knowledge. Edison is authorised and regulated by the Financial Conduct

Authority.

Edison is not an adviser or broker-dealer and does not provide investment

advice. Edison's reports are not solicitations to buy or sell any

securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison

on:

^

LinkedIn www.linkedin.com/company/edison-investment-research

Twitter www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv

°

London

+44 (0)20 3077 5700

280 High Holborn

London,

WC1V 7EE

United Kingdom

New York

+1 646 653 7026

245 Park Avenue, 39th Floor

New York, NY 10167

US

Sydney

+61 (0)2 9258 1161

Level 25 Aurora Place

88 Philip Street

Sydney NSW 2000

Australia

Frankfurt

+49 (0)69 78 8076 960

Schumannstrasse

34b

60325 Frankfurt

Germany

Die vollständige Analyse können Sie hier downloaden:

http://www.more-ir.de/d/13581.pdf

Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden

www.edisoninvestmentresearch.com.

Kontakt für Rückfragen

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.

Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung

oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.